

June 03, 2022

**To,  
Dy. General Manager  
Department of Corporate Services,  
BSE Ltd.,  
P. J. Towers, Dalal Street,  
Fort, Mumbai – 400 001**

**To,  
The Manager – Listing,  
National Stock Exchange of India Ltd.,  
Plot No. C/1, G Block,  
Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051**

**Ref: Scrip Code: 532296**

**Ref: Scrip Name: GLENMARK**

Dear Sirs,

**Sub: Transcript of the Earnings Call**

Further to our letter dated 19th May, 2022 and pursuant to Regulation 30(6) read with Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, the transcript of the Earnings call held on Monday, May 30, 2022 for the quarter and year ended March 31, 2022 has been uploaded on the Company's website at [https://glenmarkpharma.com/gpl\\_pdfs/investors/reports\\_presentations/earning\\_concall/Earnings\\_Call\\_Transcript\\_Q4FY23.pdf](https://glenmarkpharma.com/gpl_pdfs/investors/reports_presentations/earning_concall/Earnings_Call_Transcript_Q4FY23.pdf)

Request you to kindly take the same on record.

Thanking you.

Yours faithfully,  
**For Glenmark Pharmaceuticals Limited**

**Harish Kuber  
Company Secretary & Compliance Officer**

Tel: 4018 9999 / 4018 9879

Fax: 4018 9986 (Legal & Secretarial Dept.)

**Glenmark Pharmaceuticals Ltd.**

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN No: L24299MH1977PLC019982 W: [www.glenmarkpharma.com](http://www.glenmarkpharma.com)

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: [complianceofficer@glenmarkpharma.com](mailto:complianceofficer@glenmarkpharma.com)